MIM
CMPX icon

Monashee Investment Management’s Compass Therapeutics CMPX Stock Holding History

Monashee Investment Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
258,865
-741,135
-74% -$4.28M 0.74% 37
2025
Q4 		$5.37M Sell
1,000,000
-250,000
-20% -$1.15M 3.03% 14
2025
Q3 		$4.38M Buy
1,250,000
+1,085,000
+658% +$3.43M 2.18% 17
2025
Q2 		$429K Sell
165,000
-283,164
-63% -$584K 0.16% 55
2025
Q1 		$852K Hold
448,164
– – 0.1% 46
2024
Q4 		$650K Sell
448,164
-51,836
-10% -$86.1K 0.09% 37
2024
Q3 		$920K Hold
500,000
– – 0.1% 98
2024
Q2 		$500K Hold
500,000
– – 0.06% 73
2024
Q1 		$990K Hold
500,000
– – 0.12% 90
2023
Q4 		$780K Sell
500,000
-726,142
-59% -$1.26M 0.14% 35
2023
Q3 		$2.42M Sell
1,226,142
-743,154
-38% -$1.84M 1.01% 37
2023
Q2 		$6.26M Sell
1,969,296
-207,746
-10% -$652K 1.49% 14
2023
Q1 		$7.12M Sell
2,177,042
-53,399
-2% -$210K 1.97% 10
2022
Q4 		$11.2M Buy
2,230,441
+1,000,000
+81% +$3.99M 4.83% 3
2022
Q3 		$2.81M Hold
1,230,441
– – 1.04% 14
2022
Q2 		$3.26M Sell
1,230,441
-39,770
-3% -$86.3K 1.19% 7
2022
Q1 		$1.74M Sell
1,270,211
-729,789
-36% -$1.51M 0.5% 21
2021
Q4 		$6.34M Buy
+2,000,000
New +$6.63M 1.57% 8

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Monashee Investment Management's CMPX Position: Q1 2026 in Review

Monashee Investment Management reduced its Compass Therapeutics (CMPX) stake by 74% in Q1 2026, selling an estimated $4.28M and leaving 258,865 shares worth $1.37M. The position accounts for 0.74% of the portfolio, ranked #37.

Monashee Investment Management first reported a position in CMPX in Q4 2021 and has held it in 18 quarters since. The position peaked at $11.2M in Q4 2022. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Monashee Investment Management held 258,865 shares of Compass Therapeutics worth $1.37M as of Q1 2026.
  • Monashee Investment Management sold 741,135 Compass Therapeutics shares in Q1 2026, an estimated $4.28M.
  • Compass Therapeutics made up 0.74% of Monashee Investment Management's portfolio in Q1 2026, its #37 holding.
  • Monashee Investment Management first reported a position in Compass Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Monashee Investment Management's Compass Therapeutics position peaked at $11.2M in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.